---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-117691"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:09:30.752991+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics reports Q3 2024 net loss of $34M; first patients dosed in Phase 2b ACCESS obesity study

## Summary
- Cash, cash equivalents and short-term investments $915.3M; expected to fund operations through at least 2027 excluding Phase 3 registrational studies.
- Net loss $34.0M for Q3 2024 vs $23.9M in Q3 2023; R&D expenses $32.6M (up from $17.5M) driven by GLP-1R program advancement.
- First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity; topline data expected Q4 2025.
- Oral amylin receptor agonist development candidate expected by end of 2024; GIPR candidate expected H1 2025.
- ANPA-0073 (APJR agonist) Phase 2 ready; long-term toxicology studies ongoing, expected completion in 2025.

## SEC filing metadata
- accession: 0001104659-24-117691
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465924117691/0001104659-24-117691-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465924117691/tm2428324d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-117691
- JSON: https://secwatch.observer/filing/0001104659-24-117691.json
- Plain text: https://secwatch.observer/filing/0001104659-24-117691.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.